The QR4 algorithm for prediction of 10-year cardiovascular disease risk, developed, tested and externally validated in datasets comprising 16.8 million people from the United Kingdom, improves upon the QRISK3 algorithm that is in current use by incorporating new risk factors.

An exploratory analysis of the 1-year clinical trial PASADENA in individuals with early-stage Parkinson’s disease suggests that prasinezumab might reduce motor signs progression to a greater extent in those with more rapidly progressing disease.

Developed on cytology images of hydrothorax and ascites from 57,220 cases at four hospitals, a deep-learning model shows high accuracy in tumor origin prediction and presents prognostic value when patient treatment is consistent with the cancer origin predicted by the model.

The cellular and molecular mechanisms underlying the health impacts of climate change must be better understood in order to plan interventions that mitigate harm.

An antibody screen of two distinct multiple sclerosis cohorts reveals an autoantibody signature that is detectable years before symptom onset and linked to a common microbial motif.

In a series of clinically relevant tasks in computational pathology, AI-driven models display marked performance disparities across demographic groups, which can only partially be mitigated by self-supervision on large training datasets and existing debiasing techniques.

Implementation of organized low-dose computed tomography screening in over 4,000 individuals with high risk for lung cancer as part of the Ontario Lung Cancer Screening Pilot reported high cancer detection rates, early detection of cancer and low serious harms.

The QR4 algorithm for prediction of 10-year cardiovascular disease risk, developed, tested and externally validated in datasets comprising 16.8 million people from the United Kingdom, improves upon the QRISK3 algorithm that is in current use by incorporating new risk factors.

A self-amplifying mRNA vaccine shows promise in this new modality by eliciting neutralizing antibodies against the SARS-CoV-2 Omicron (BA.1) variant in a phase 2/3 trial.

The posterior hippocampal tail is an important seizure node in humans and may be a promising interventional target in epilepsy.

The cellular and molecular mechanisms underlying the health impacts of climate change must be better understood in order to plan interventions that mitigate harm.

As evidence emerges describing the accumulation of small plastic particles in various organs and tissues of the body, a much deeper understanding of the effects of these particles on human health is urgently needed.

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.